UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
CUE BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|
Delaware (State of incorporation or organization) |
47-3324577 (I.R.S. Employer Identification No.) |
|
675 W. Kendall Street Cambridge, MA (Address of principal executive offices) |
02142 (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title of each class to be so registered |
Name of each exchange on which each class is to be registered |
| Common Stock, par value $0.001 per share | The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨
Securities Act registration statement file number to which this form relates: 333-220550.
Securities to be registered pursuant to Section 12(g) of the Act:
None
(Title of class)
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant’s Securities to be Registered.
The description of Cue Biopharma, Inc.’s (the “Registrant”) common stock, par value $0.001 per share (the “Common Stock”), required by this Item is contained in the Registrant’s Registration Statement on Form S-1 (Registration No. 333-220550) initially filed with the Securities and Exchange Commission on September 21, 2017, and as subsequently amended (the “Registration Statement”), under the caption “Description of Capital Stock,” and is incorporated herein by reference. The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes a part of the Registration Statement shall also be deemed to be incorporated herein by reference.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 13th day of December, 2017.
| CUE BIOPHARMA, INC. | |||
| Date: December 13, 2017 | By: | /s/ Daniel Passeri | |
| Name: | Daniel Passeri | ||
| Title: | Chief Executive Officer | ||